Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Med Virol
    March 2024
  1. XIE M, Wang Z, Zhao F, Li Y, et al
    Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles.
    J Med Virol. 2024;96:e29502.
    >> Share

  2. YANG J, Xu S, Cheng J, Yin X, et al
    CXCL10 and its receptor in patients with chronic hepatitis B and their ability to predict HBeAg seroconversion during antiviral treatment with TDF.
    J Med Virol. 2024;96:e29516.
    >> Share

  3. TRUNFIO M, Tang B, Okwuegbuna O, Iudicello JE, et al
    Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers.
    J Med Virol. 2024;96:e29550.
    >> Share

    February 2024
  4. CHANG LC, Chen IW, Hung KC
    Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.
    J Med Virol. 2024;96:e29464.
    >> Share

  5. OMBELET S, Castanares-Zapatero D, Desimpel F, Hulstaert F, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    J Med Virol. 2024;96:e29434.
    >> Share

    January 2024
  6. PALOMINO-CABRERA R, Tejerina F, Molero-Salinas A, Veintimilla C, et al
    No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir/ritonavir.
    J Med Virol. 2024;96:e29337.
    >> Share

  7. DURSTENFELD MS, Peluso MJ, Lin F, Peyser ND, et al
    Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    J Med Virol. 2024;96:e29333.
    >> Share

    December 2023
  8. ZHOU Y, Liu Y, Jiang L, Zhang R, et al
    Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    J Med Virol. 2023;95:e29318.
    >> Share

    November 2023
  9. CHEN YC, Hsu CW, Chien RN
    Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.
    J Med Virol. 2023;95:e29213.
    >> Share

    October 2023
  10. LIU J, Zhang H, Kong J, Liu S, et al
    Alleviated symptoms of SARS-CoV-2 Omicron variant infection in chronic hepatitis B patients with immune control.
    J Med Virol. 2023;95:e29173.
    >> Share

  11. LAGI F, Giacomelli A, Borghi V, Ciccullo A, et al
    Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    J Med Virol. 2023;95:e29149.
    >> Share

  12. OOMEN PGA, Dijkstra S, Hofstra LM, Nijhuis MM, et al
    Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study.
    J Med Virol. 2023;95:e29178.
    >> Share

    September 2023
  13. CASO JM, Fernandez-Ruiz M, Lopez-Medrano F, Caro-Teller JM, et al
    Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience.
    J Med Virol. 2023;95:e29082.
    >> Share

  14. BRUZZESI E, Gabrieli A, Bernasconi D, Marchetti G, et al
    HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
    J Med Virol. 2023;95:e29114.
    >> Share

    August 2023
  15. LIU TH, Chuang MH, Wu JY, Huang PY, et al
    Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study.
    J Med Virol. 2023;95:e28992.
    >> Share

  16. WANG Y, Zhao D, Xiao W, Shi J, et al
    Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge.
    J Med Virol. 2023;95:e29014.
    >> Share

    July 2023
  17. LIU TH, Wu JY, Huang PY, Tsai YW, et al
    The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
    J Med Virol. 2023;95:e28951.
    >> Share

    June 2023
  18. ZENG G, Wang L, Li J, Zhang Z, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19.
    J Med Virol. 2023;95:e28836.
    >> Share

  19. RANARD BL, Chow CC, Megjhani M, Asgari S, et al
    A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
    J Med Virol. 2023;95:e28854.
    >> Share

  20. TSAI YW, Wu JY, Liu TH, Chuang MH, et al
    Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    J Med Virol. 2023;95:e28869.
    >> Share

  21. WU JY, Liu MY, Liu TH, Chuang MH, et al
    Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19.
    J Med Virol. 2023;95:e28866.
    >> Share

  22. AMANI B, Akbarzadeh A, Amani B, Shabestan R, et al
    Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28889.
    >> Share

    May 2023
  23. LIU TH, Huang PY, Wu JY, Chuang MH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    J Med Virol. 2023;95:e28801.
    >> Share

    April 2023
  24. COX S, Margot N, Callebaut C
    Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
    J Med Virol. 2023;95:e28723.
    >> Share

  25. DENG G, Li D, Sun Y, Jin L, et al
    Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    J Med Virol. 2023;95:e28756.
    >> Share

  26. CHUANG MH, Wu JY, Liu TH, Hsu WH, et al
    Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    J Med Virol. 2023;95:e28750.
    >> Share

  27. TIAN F, Chen Z, Feng Q
    Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    J Med Virol. 2023;95:e28732.
    >> Share

    March 2023
  28. TRUNFIO M, Pinnetti C, Arsuffi S, Bai F, et al
    The Presence of Resistance-associated Mutations in Reverse Transcriptase Gene is Associated with Cerebrospinal Fluid HIV-1 Escape: a multicentric retrospective analysis.
    J Med Virol. 2023 Mar 26. doi: 10.1002/jmv.28704.
    >> Share

  29. SHARMA A, Roy S, Sharma R, Kumar A, et al
    Association of anti-viral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms.
    J Med Virol. 2023 Mar 14. doi: 10.1002/jmv.28671.
    >> Share

    February 2023
  30. GUO Y, Guo Y, Zhang Y, Li F, et al
    Factors Affecting Prolonged SARS-CoV-2 Infection and Development and Validation of Predictive Nomograms.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28550.
    >> Share

    January 2023
  31. QI T, Jin Y, Wang H, Liao Y, et al
    Nirmatrelvir-ritonavir Therapy and COVID-19 Vaccination Improve Clinical Outcomes of SARS-CoV-2 Omicron Variant Infection.
    J Med Virol. 2023 Jan 18. doi: 10.1002/jmv.28497.
    >> Share

  32. CHEEMA HA, Jafar U, Sohail A, Shahid A, et al
    Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    J Med Virol. 2023 Jan 6. doi: 10.1002/jmv.28471.
    >> Share

  33. SUDA G, Baba M, Yamamoto Y, Sho T, et al
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28452.
    >> Share

    December 2022
  34. WANG Y, Zhao D, Liu X, Chen X, et al
    Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 omicron variants.
    J Med Virol. 2022 Dec 29. doi: 10.1002/jmv.28443.
    >> Share

  35. AMANI B, Amani B
    Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19 : a rapid review and meta-analysis.
    J Med Virol. 2022 Dec 28. doi: 10.1002/jmv.28441.
    >> Share

  36. LAI CC, Hsueh PR
    Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28430.
    >> Share

  37. WANG Y, Chen X, Liu X, Zhao D, et al
    Nirmatrelvir-ritonavir might only be effective in elderly patients.
    J Med Virol. 2022 Dec 21. doi: 10.1002/jmv.28418.
    >> Share

    October 2022
  38. VALENTINA M, Alessandro CL, Francesca C, Silvia R, et al
    Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    J Med Virol. 2022 Oct 2. doi: 10.1002/jmv.28186.
    >> Share

    July 2022
  39. LAN J, Li W, Yu R, Syed F, et al
    Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naive and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors.
    J Med Virol. 2022 Jul 15. doi: 10.1002/jmv.28005.
    >> Share

  40. LIAN J, Kuang W, Jia H, Lu Y, et al
    Pegylated interferon-alpha-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naive HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomize
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28003.
    >> Share

  41. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    >> Share

    June 2022
  42. AGUILAR G, Truong HM, Ovelar P, Samudio T, et al
    HIV Drug Resistance in Persons Initiating or Re-initiating First-line Antiretroviral Therapy in Paraguay: Results of a National Patient Survey.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27933.
    >> Share

  43. ASHURO AA, Zhang SC, Wang T, Chu QS, et al
    The Effect of protease inhibitors-based antiretroviral therapy on serum/plasma interleukin-6 levels among PLHIV: a systematic review and meta-analysis.
    J Med Virol. 2022 Jun 6. doi: 10.1002/jmv.27912.
    >> Share

    May 2022
  44. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27863.
    >> Share

    March 2022
  45. FIORE BD, Andrea V, Giuseppe P, Yagai B, et al
    Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27754.
    >> Share

  46. HASSANIAZAD M, Farshidi H, Gharibzadeh A, Bazram A, et al
    Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with covid-19: a randomized clinical trial.
    J Med Virol. 2022 Mar 16. doi: 10.1002/jmv.27724.
    >> Share

    February 2022
  47. CHIU W, Verschueren L, Eynde CVD, Buyck C, et al
    Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27683.
    >> Share

    December 2021
  48. WANG Z, Yang L
    In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery.
    J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27540.
    >> Share

  49. CHENG Q, Zhao G, Chen J, Jia Q, et al
    Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials.
    J Med Virol. 2021 Dec 9. doi: 10.1002/jmv.27512.
    >> Share

    November 2021
  50. YU M, Wang DC, Li S, Lei YH, et al
    Meta-analysis of arbidol versuslopinavir/ritonavir in the treatment of coronavirus disease 2019.
    J Med Virol. 2021 Nov 27. doi: 10.1002/jmv.27481.
    >> Share

    October 2021
  51. RAHMAN S, Sarker MS, Aralaguppe SG, Sarwar G, et al
    Drug resistance pattern among ART-naive clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2021 Oct 12. doi: 10.1002/jmv.27387.
    >> Share

    September 2021
  52. SARGIN ALTUNOK E, Satici C, Dinc V, Kamat S, et al
    Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave vs the second wave.
    J Med Virol. 2021 Sep 7. doi: 10.1002/jmv.27319.
    >> Share

    July 2021
  53. KALANTARI S, Fard SR, Maleki D, Taher MT, et al
    Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    J Med Virol. 2021 Jul 13. doi: 10.1002/jmv.27195.
    >> Share

    June 2021
  54. DA SILVA PRATES G, Malta FM, de Toledo Goncalves F, Monteiro MA, et al
    AIDS incidence and survival in a hospital-based cohort of HIV-positive patients from Sao Paulo, Brazil: The role of IFN-lambda4 polymorphisms.
    J Med Virol. 2021;93:3601-3606.
    >> Share

    May 2021
  55. MANGANOTTI P, Bellavita G, Tommasini V, D'Acunto L, et al
    Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathies patients.
    J Med Virol. 2021 May 5. doi: 10.1002/jmv.27061.
    >> Share

    April 2021
  56. AGHAJANI MH, Moradi O, Amini H, Tehrani HA, et al
    Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27053.
    >> Share

  57. MOVAHED SMM, Akhavizadegan H, Dolatkhani F, Nejadghaderi SA, et al
    Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: a retrospective study.
    J Med Virol. 2021 Apr 1. doi: 10.1002/jmv.26992.
    >> Share

    March 2021
  58. ARRAIS CRA, Lima K, Barreiros M, Rodrigues JKF, et al
    HIV-1 Subtypes and Drug Resistance in Children During Antiretroviral Therapy in Brazil.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26988.
    >> Share

  59. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    >> Share

    January 2021
  60. KHEIRABADI D, Haddad F, Mousavi-Roknabadi RS, Rezaeisadrabadi M, et al
    A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for current COVID-19 (SARS-CoV-2) pandemic.
    J Med Virol. 2021 Jan 19. doi: 10.1002/jmv.26811.
    >> Share

  61. XIA Q, Xu K, Ni Q, Li Y, et al
    Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.
    J Med Virol. 2021 Jan 15. doi: 10.1002/jmv.26798.
    >> Share

    December 2020
  62. LATHOUWERS E, Weinsteiger S, Baugh B, Ghys A, et al
    Week 96 resistance analyses of the once-daily, Single-tablet Regimen (STR) Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
    J Med Virol. 2020 Dec 10. doi: 10.1002/jmv.26721.
    >> Share

    November 2020
  63. WANG J, Zhu L, Xue L, Liu L, et al
    Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: a retrospective, multi-center study.
    J Med Virol. 2020 Nov 11. doi: 10.1002/jmv.26663.
    >> Share

    September 2020
  64. MONDI A, Cimini E, Colavita F, Cicalini S, et al
    COVID-19 in people living with HIV: clinical implications of dynamics of immune response to SARS-CoV-2.
    J Med Virol. 2020 Sep 25. doi: 10.1002/jmv.26556.
    >> Share

    August 2020
  65. BURGOS-BLASCO B, Guemes-Villahoz N, Vidal-Villegas B, Donate-Lopez J, et al
    Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir.
    J Med Virol. 2020 Aug 12. doi: 10.1002/jmv.26420.
    >> Share

  66. PATEL RH, Acharya A, Mohan M, Byrareddy SN, et al
    COVID-19 and AIDS: outcomes from the co-existence of two global pandemics and the importance of chronic antiretroviral therapy.
    J Med Virol. 2020 Aug 11. doi: 10.1002/jmv.26416.
    >> Share

  67. GIACOMELLI A, Pagani G, Ridolfo AL, Bit LO, et al
    Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.
    J Med Virol. 2020 Aug 10. doi: 10.1002/jmv.26407.
    >> Share

  68. UCHIDA Y, Nakao M, Tsuji S, Uemura H, et al
    Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    J Med Virol. 2020;92:1370.
    >> Share

    July 2020
  69. KANWUGU ON, Adadi P
    HIV/SARS-CoV-2 coinfection: a global perspective.
    J Med Virol. 2020 Jul 21. doi: 10.1002/jmv.26321.
    >> Share

  70. CHANDRASEKAR VT, Venkatesalu B, Patel HK, Spadaccini M, et al
    Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection.
    J Med Virol. 2020 Jul 15. doi: 10.1002/jmv.26302.
    >> Share

  71. MARIMUTHU J, Kumar BS, Aravind Gandhi P
    HIV and SARS CoV-2 co-infection: A retrospective, record based, case series from South India.
    J Med Virol. 2020 Jul 7. doi: 10.1002/jmv.26271.
    >> Share

  72. YU C, Zhang Z, Guo Y, Shi J, et al
    Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.
    J Med Virol. 2020 Jul 4. doi: 10.1002/jmv.26260.
    >> Share

    June 2020
  73. RUAN Z, Liu C, Guo Y, He Z, et al
    SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).
    J Med Virol. 2020 Jun 24. doi: 10.1002/jmv.26222.
    >> Share

  74. XIAO L, Wu X, Zhang F, Wang J, et al
    Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1 b hepatitis C infection.
    J Med Virol. 2020 Jun 11. doi: 10.1002/jmv.26161.
    >> Share

  75. ZHANG Z, Wang S, Tu X, Peng X, et al
    A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
    J Med Virol. 2020 Jun 5. doi: 10.1002/jmv.26141.
    >> Share

  76. ZUO Y, Liu Y, Zhong Q, Zhang K, et al
    Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
    J Med Virol. 2020 Jun 3. doi: 10.1002/jmv.26127.
    >> Share

    May 2020
  77. BALUKU JB, Mwebaza S, Ingabire G, Nsereko C, et al
    HIV and SARS-CoV-2 co-infection: A case report from Uganda.
    J Med Virol. 2020 May 21. doi: 10.1002/jmv.26044.
    >> Share

  78. CHONG VH, Chong PL, Metussin D, Asli R, et al
    Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.
    J Med Virol. 2020 May 13. doi: 10.1002/jmv.26004.
    >> Share

  79. MUSARRAT F, Chouljenko V, Dahal A, Nabi R, et al
    The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.
    J Med Virol. 2020 May 6. doi: 10.1002/jmv.25985.
    >> Share

    April 2020
  80. RUBEL AR, Chong PL, Abdullah MS, Asli R, et al
    Letter to the Editor: Lipemic serum in patients with COVID-19 undergoing treatment.
    J Med Virol. 2020 Apr 28. doi: 10.1002/jmv.25942.
    >> Share

    March 2020
  81. WAN S, Xiang Y, Fang W, Zheng Y, et al
    Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing.
    J Med Virol. 2020 Mar 21. doi: 10.1002/jmv.25783.
    >> Share

  82. CHEN Q, Quan B, Li X, Gao G, et al
    A report of clinical diagnosis and treatment of 9 cases of coronavirus disease 2019.
    J Med Virol. 2020 Mar 12. doi: 10.1002/jmv.25755.
    >> Share

  83. ZHU F, Cao Y, Xu S, Zhou M, et al
    Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
    J Med Virol. 2020 Mar 11. doi: 10.1002/jmv.25732.
    >> Share

    February 2020
  84. YAO TT, Qian JD, Zhu WY, Wang Y, et al
    A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option.
    J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25729.
    >> Share

  85. HAN W, Quan B, Guo Y, Zhang J, et al
    The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019.
    J Med Virol. 2020 Feb 19. doi: 10.1002/jmv.25711.
    >> Share

    January 2020
  86. TAMAKI N, Kurosaki M, Nakanishi H, Itakura J, et al
    Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
    J Med Virol. 2020 Jan 29. doi: 10.1002/jmv.25692.
    >> Share

  87. MOHAMAD ISA II, Abu Bakar S, Ab Rahman AK
    Ethnicity as predictor of immune reconstitution among Malaysian HIV-positive patients treated with highly active antiretroviral therapy (HAART).
    J Med Virol. 2020 Jan 20. doi: 10.1002/jmv.25680.
    >> Share

    December 2019
  88. FUCHS M, Monto A, Brau N, Charafeddine M, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders.
    J Med Virol. 2019 Dec 12. doi: 10.1002/jmv.25655.
    >> Share

    November 2019
  89. UCHIDA Y, Nakao M, Tsuji S, Uemura H, et al
    Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    J Med Virol. 2019 Nov 28. doi: 10.1002/jmv.25644.
    >> Share

    October 2019
  90. REN L, Wang B, Miao Z, Liu P, et al
    A Correlation Analysis of HHV Infection and Its Predictive Factors in An HIV-seropositive Population in Yunnan, China.
    J Med Virol. 2019 Oct 17. doi: 10.1002/jmv.25609.
    >> Share

  91. WANG YH, Liao J, Zhang DM, Wu DB, et al
    Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
    J Med Virol. 2019 Oct 14. doi: 10.1002/jmv.25608.
    >> Share

    May 2019
  92. LI J, Lai H, Chen S, Kickler T, et al
    Cocaine use modifies the association between antiretroviral therapy and endothelial dysfunction among adults with HIV infection.
    J Med Virol. 2019 May 29. doi: 10.1002/jmv.25507.
    >> Share

    March 2019
  93. WEI X, Zhang Y, Santella AJ, Wang L, et al
    Effect of early highly active antiretroviral therapy on viral suppression among newly diagnosed men who have sex with men living with HIV in Xi'an, China.
    J Med Virol. 2019 Mar 6. doi: 10.1002/jmv.25449.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016